NT-33 * NAD+ SYNTHESIS INHIBITION AS A THERAPEUTIC STRATEGY FOR GLIOBLASTOMA WITH MYC AMPLIFICATION
NT-33 * NAD+ SYNTHESIS INHIBITION AS A THERAPEUTIC STRATEGY FOR GLIOBLASTOMA WITH MYC AMPLIFICATION
BACKGROUND AND OBJECTIVE: Oncoprotein Myc is a master transcription factor and plays a crucial role in human cancer pathogenesis and the stem-like phenotype of glioblastoma (GBM). Since dyregulated Myc in cancer drives altered glucose and glutamine metabolism promoting tumor growth, pathways involved in Myc-induced aberrant metabolism could offer therapeutic targets. The coenzyme Nicotinamide Adenine Dinucleotide (NAD+) is essential in redox reactions including glycolysis and the citric acid cycle. We sought to determine whether MYC-amplified GBM, as compared to MYC-non-amplified GBM, utilizes distinct NAD+ biosynthesis pathways and exhibits differential dependence on metabolic pathways that require NAD+. MATERIALS AND METHODS: A total of 11 patient-derived GBM stem-like cell (GSCs) lines established from surgical specimens were used. FISH analysis was performed to determine copy number status of MYC and MYCN. Expression of enzymes involved in NAD+ synthesis [e.g., nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyltransferase (NAPRT-1)] was tested with Western blot. NAD+ levels were measured after treating GSCs with FK866, a potent and specific small molecule inhibitor for NAMPT. The effects of pharmacological inhibition of NAMPT on GSC viability were determined by CellTiter Glo cell viability assay. RESULTS: Five (45.5%) GSCs had MYC (1) or MYCN (4) amplification. FK866 depleted NAD+ levels in GSCs. Treatment with FK866 potently inhibited in vitro growth of all the GSCs that harbored MYC/MYCN amplification with IC50 values in a low-nanomolar range (0.7 - 4.6 nM). In contrast, non-amplified GSCs as well as human normal astrocytes showed resistance to FK866. The MYC/MYCN amplified GSCs expressed low or undetectable levels of NAPRT-1, which is involved in the NAD+ synthesis pathway utilizing nicotinic acid. CONCLUSIONS: MYC/MYCN-amplified GSCs, but not non-amplified GSCs, were exquisitely sensitive to NAMPT inhibition. NAMPT may represent a promising therapeutic target for GBM with MYC amplification.
- Harvard University United States
- Massachusetts General Hospital United States
4 Research products, page 1 of 1
- 2021IsAmongTopNSimilarDocuments
- 2018IsAmongTopNSimilarDocuments
- 2013IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
